On September 10, 2020 ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, reported its participation in H.C. Wainwright & Co., 22nd Annual Investment Conference being held virtually September 14-16 2020 (Press release, ProMIS Neurosciences, SEP 10, 2020, https://promisneurosciences.com/news/promis-neurosciences-to-participate-in-h-c-wainwright-co-22nd-annual-investment-conference/ [SID1234564920]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

ProMIS’ Executive Chairman, Eugene Williams, will provide an update on the company with special focus on the opportunities to detect, treat and ultimately prevent Alzheimer’s disease.

Mr. Williams’ webcast presentation is scheduled for Tuesday, September 15, 2020 at 1:00 pm ET. The webcast will be available live and approximately 24 hours following the live presentation through the following link here and on the Company’s website.